You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

IDH-mutant astocytoma

Showing 1 - 25 of 751
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult Trial (NEO212 Oral Capsule, Ipilimumab,

Not yet recruiting
  • Diffuse Astrocytoma, IDH-Mutant
  • +20 more
  • NEO212 Oral Capsule
  • +8 more
  • (no location specified)
Sep 18, 2023

Adult Gliomas, Mixed Trial in San Francisco (Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG), Magnetic Resonance Image

Recruiting
  • Adult Gliomas, Mixed
  • Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG)
  • Magnetic Resonance Image (MRI)
  • San Francisco, California
    University of California, San Francisco
May 9, 2023

Astrocytoma Trial (Vorasidenib, Pembrolizumab)

Not yet recruiting
  • Astrocytoma
  • (no location specified)
Aug 1, 2022

Astrocytoma, Oligodendroglioma, Adult, Glioma, Malignant Trial in Saint Louis (temporally-modulated pulsed radiotherapy (TMPRT))

Recruiting
  • Astrocytoma
  • +2 more
  • temporally-modulated pulsed radiotherapy (TMPRT)
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 19, 2023

Glioblastoma Trial in Beijing (PLB1001, Temozolomide, Cisplatin combined with Etoposide)

Active, not recruiting
  • Glioblastoma
  • Beijing, Beijing, China
    Beijing Tiantan Hospital,Capital Medical University
Oct 27, 2023

Glioma, IDH Mutation, Astrocytoma Trial in Philadelphia (Retifanlimab, All-trans retinoic acid)

Not yet recruiting
  • Glioma
  • +3 more
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Jul 22, 2022

Cholangiocarcinoma With IDH1 Mutation, Solid Tumors With IDH1 Mutation Trial in Beijing (AB-218 capsule)

Not yet recruiting
  • Cholangiocarcinoma With IDH1 Mutation
  • Solid Tumors With IDH1 Mutation
  • AB-218 capsule
  • Beijing, Beijing, China
    Peking Union Medical College Hospital, Chinese Academy of Medica
Apr 2, 2023

Glioma, Gliomas, High Grade Glioma Trial run by the National Cancer Institute (NCI) (3T MRI scanner)

Recruiting
  • Glioma
  • +4 more
  • 3T MRI scanner
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

IDH1-mutant Cholangiocarcinoma Trial (Ivosidenib, Recommended Combination Dose (RCD) of ivosidenib, Nivolumab)

Not yet recruiting
  • IDH1-mutant Cholangiocarcinoma
  • (no location specified)
Jun 29, 2023

Low Grade Glioma of Brain Trial in Durham (PEPIDH1M vaccine + vorasidenib)

Not yet recruiting
  • Low Grade Glioma of Brain
  • PEPIDH1M vaccine + vorasidenib
  • Durham, North Carolina
    Duke University Medical Center
Nov 2, 2022

Gliomas Trial in Miami, Boston, New York (Nivolumab)

Active, not recruiting
  • Gliomas
  • Miami, Florida
  • +3 more
May 5, 2022

IDH-mutant and IDH-wildtype Glioma Patients After

Recruiting
  • Glioma
  • RS-fMRI
  • Saint Louis, Missouri
    Washington University School of Medicine
Mar 8, 2022

Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia Trial in Baltimore, Boston, Columbus (Enasidenib)

Active, not recruiting
  • Acute Myeloid Leukemia
  • Chronic Myelomonocytic Leukemia
  • Baltimore, Maryland
  • +3 more
Aug 8, 2022

Advanced Solid Tumor, IDH1 Mutation, Glioma Trial in Pittsburgh (ivosidenib and nivolumab)

Recruiting
  • Advanced Solid Tumor
  • +2 more
  • ivosidenib and nivolumab
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Mar 14, 2022

Glioblastoma Multiforme, Adult, Glioblastoma, IDH-mutant Trial (Dose escalation + Reduced Margin Adaptive Radiotherapy)

Not yet recruiting
  • Glioblastoma Multiforme, Adult
  • Glioblastoma, IDH-mutant
  • Dose escalation + Reduced Margin Adaptive Radiotherapy
  • (no location specified)
Oct 3, 2022

Glioma Trial (AB-218)

Not yet recruiting
  • Glioma
  • (no location specified)
Mar 29, 2022

Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia

Recruiting
  • Acute Myeloid Leukemia
  • +6 more
  • Biospecimen Collection
  • +2 more
  • Orange, California
  • +9 more
Jan 27, 2023

Epilepsy; Seizure Trial (ES-481)

Withdrawn
  • Epilepsy; Seizure
  • (no location specified)
Mar 28, 2022

Vascular Habitats Within Astrocytoma Grade 4 at Molecular,

Recruiting
  • Astrocytoma, Grade IV
  • +7 more
    • Valencia, Spain
      Biomedical Data Science Lab. Universitat Politècnica de València
    May 11, 2022

    IDH1 Mutation Myeloid Tumors Trial in Baltimore, Boston, Columbus (Ivosidenib)

    Active, not recruiting
    • IDH1 Mutation Myeloid Neoplasms
    • Baltimore, Maryland
    • +3 more
    Oct 25, 2021

    Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia Trial in Baltimore,

    Active, not recruiting
    • Acute Myeloid Leukemia
    • +6 more
    • Baltimore, Maryland
    • +2 more
    Feb 25, 2022

    Oligodendroglioma, Oligodendroglioma, Anaplastic, Diffuse Astrocytoma, IDH-Mutant Trial in Oslo (Radiation therapy)

    Recruiting
    • Oligodendroglioma
    • +2 more
    • Radiation therapy
    • Oslo, Norway
      Oslo University Hospital
    Jan 14, 2022

    Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3 Trial in United States (other, radiation, drug)

    Active, not recruiting
    • Astrocytoma, IDH-Mutant, Grade 2
    • Astrocytoma, IDH-Mutant, Grade 3
    • Questionnaire Administration
    • +3 more
    • Phoenix, Arizona
    • +24 more
    Dec 7, 2022

    Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Decitabine and

    Recruiting
    • Acute Myeloid Leukemia
    • +2 more
    • Decitabine and Cedazuridine
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jun 29, 2022

    Glioma, IDH Mutation Trial (BAY 2402234)

    Withdrawn
    • Glioma
    • IDH Mutation
    • BAY 2402234
    • (no location specified)
    Dec 17, 2021